Proposal to list ceftaroline fosamil in Section H of the Pharmaceutical Schedule
PHARMAC is seeking feedback on a proposal to list ceftaroline fosamil in Part II of Section H of the Pharmaceutical Schedule, through a provisional agreement with AstraZeneca Limited.
In summary, this proposal is to list ceftaroline fosamil for use in DHB hospitals for multi-resistant organism salvage therapy from 1 November 2014.
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Friday, 19 September 2014 to:
Senior Therapeutic Group Manager
PO Box 10 254
Fax: 04 460 4995
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate acting under delegated authority) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like withheld.
Details of the proposal
Ceftaroline fosamil would be listed in Part II of Section H of the Pharmaceutical Schedule at the following price from 1 November 2014 (ex-manufacturer, excluding GST):
|Ceftaroline fosamil||Inj 600 mg vial||Zinforo||10||$1,450.00|
Ceftaroline fosamil would be listed subject to the following restriction in Part II of Section H of the Pharmaceutical Schedule: